158 articles with Certara Corporation
Certara, Inc., a global leader in biosimulation, announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders at a price to the public of $25.00 per share.
Certara, Inc., a global leader in biosimulation, announced that it is set to join the Russell 1000® Index, effective after the U.S. market open on March 22, 2021, according to a preliminary list of quarterly IPO additions posted February 26, 2021.
Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 Guidance
Certara, Inc., a global leader in biosimulation, reported its preliminary results for the fourth quarter and full year ended December 31, 2020.
The Year 2020 Marks the 7th Consecutive Year Certara Customers Received 90 Percent of US FDA Novel Drug and Biologic Approvals
Affirms continued regulatory and industry adoption of biosimulation and technology to bring new drugs to patients
12/11/2020Another four companies join the Nasdaq, bringing the life science IPO count to over 70 this year.
Office will support rapid growth and collaboration with customers in China to accelerate biopharmaceutical R&D
60 Degrees Pharmaceuticals Announces Positive Results of Cell Culture Testing of ARAKODA® (tafenoquine) for COVID-19
In vitro testing demonstrates that tafenoquine exhibits antiviral activity against SARS-CoV-2
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
Certara and DMTC Ltd Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Workers at High Risk for COVID-19
Certara applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19
Certara Launches New Version of Simcyp® Simulator for Population-Based Pharmacokinetic Modeling and Simulation
Version 19 offers mechanistic models for assessing maternal-fetal drug risk, developing drug formulations, and optimizing dermal and transdermal drug development
Funded by the Bill & Melinda Gates Foundation, the online Center helps accelerate therapeutics for COVID-19 by integrating clinical pharmacology, innovation and collaboration
Scilligence, an innovation leader of unified informatics platform for biologics and small molecules drug R&D, has partnered with Certara to enable advanced data analysis and visualization capabilities.
Certara®, the global model-informed drug development and decision support leader, today announced the availability of PK Submit™, a technology solution for automating the creation of PK Clinical Data Interchange Standards Consortium (CDISC) domains during Non-Compartmental Analysis (NCA
Certara Scientists to Present Their Latest Modeling and Simulation Advances at 2019 AAPS PharmSci 360
Certara will host two Phoenix WinNonlin™ Lunch and Learns and also lead 18 workshop, presentation and poster sessions on model-informed drug development
Presentations demonstrate how to employ real-world evidence to compare the cost-effectiveness and therapeutic benefit of different medical interventions
Certara®, the global model-informed drug development and decision support leader, today announced that it is celebrating the 20th anniversary of its Simcyp® Consortium.
Certara Launches BaseCase Data Studio, Enabling Pharma and MedTech Clients to Conduct Advanced Data Analyses During Value-Based Product Discussions
BaseCase platform can now perform live statistical modeling and sophisticated data analyses, delivering evidence-based claims to support value messages during payer, provider and HCP discussions
Certara Introduces Its Hasharc Decentralized Application for Healthcare at the Launch of Hedera Hashgraph Open Access
New Certara DApp provides transaction insights on Hedera network and supports data provenance for supply chain uses cases, improving transparency and disclosure for healthcare clients
Certara Launches Version 8.2 of Its Industry-Leading Phoenix PK/PD Modeling and Simulation Software for Drug Development
Certara®, the global model-informed drug development and decision support leader, today announced the launch of Phoenix® 8.2, the industry gold standard in pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation software for drug development.
Certara®, the global model-informed drug development and decision support leader, today announced the launch of version 19.6 of D360, its scientific informatics platform for drug discovery and development